Corbus Pharmaceuticals appoints new board chair
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Corbus Pharmaceuticals Holding (CRBP)
Corbus Pharmaceuticals Holding stock price live, this page displays NASDAQ CRBP stock exchange data. View the CRBP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Corbus Pharmaceuticals Holding real time stock price chart below.
What Is the Corbus Pharmaceuticals Holding Stock Price Today?
The Corbus Pharmaceuticals Holding stock price today is 7.3201.
What Is the Stock Symbol for Corbus Pharmaceuticals Holding?
The stock symbol for Corbus Pharmaceuticals Holding is "CRBP."
What Stock Exchange Does Corbus Pharmaceuticals Holding Trade On?
Corbus Pharmaceuticals Holding is listed and trades on the NASDAQ stock exchange.
Is Corbus Pharmaceuticals Holding a Good Stock to Buy?
Determining whether Corbus Pharmaceuticals Holding—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CRBP quote. (ISIN: US21833P3010)
What Is the Corbus Pharmaceuticals Holding Stock Price Today?
The Corbus Pharmaceuticals Holding stock price today is 7.3201.
What Is the Stock Symbol for Corbus Pharmaceuticals Holding?
The stock symbol for Corbus Pharmaceuticals Holding is "CRBP."
What Stock Exchange Does Corbus Pharmaceuticals Holding Trade On?
Corbus Pharmaceuticals Holding is listed and trades on the NASDAQ stock exchange.
Is Corbus Pharmaceuticals Holding a Good Stock to Buy?
Determining whether Corbus Pharmaceuticals Holding—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CRBP quote. (ISIN: US21833P3010)
7.3201
-0.0199(-0.27%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.0985
7.5750
52 wk Range
4.6400
61.9000
CRBP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CRBP is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.09857.5750
52 wk Range
4.640061.9000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CRBP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
46.2222
Upside
+531.44%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings downwards for the upcoming period
Corbus Pharmaceuticals Holding Company Profile
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Corbus Pharmaceuticals Holding SWOT Analysis
Promising Pipeline | Explore Corbus Pharmaceuticals' diverse portfolio, featuring potential best-in-class therapies for cancer and obesity, positioning the company for significant market impact |
Financial Fortitude | Delve into Corbus's robust financial position, with $120.1 million in cash reserves providing runway for key development milestones and future growth |
Market Opportunity | Learn how Corbus targets lucrative markets in oncology and obesity, with analysts projecting billion-dollar sales potential for lead candidates |
Analyst Outlook | Discover the bullish sentiment among analysts, with price targets ranging from $77 to $85, reflecting confidence in Corbus's innovative approach and market potential |
Compare CRBP to Peers and Sector
Metrics to compare | CRBP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRBPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −1.8x | −0.5x | |
PEG Ratio | −0.05 | −0.01 | 0.00 | |
Price/Book | 0.7x | 1.0x | 2.6x | |
Price / LTM Sales | - | 17.9x | 3.0x | |
Upside (Analyst Target) | - | 202.1% | 54.1% | |
Fair Value Upside | Unlock | 6.0% | 8.7% | Unlock |
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 46.2222
(+531.44% Upside)
Earnings
Latest Release
Mar 11, 2025
EPS / Forecast
-0.78 / -1.77
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Corbus Pharmaceuticals Holding (CRBP) Stock Price Today?
The Corbus Pharmaceuticals Holding stock price today is 7.32
What Stock Exchange Does Corbus Pharmaceuticals Holding Trade On?
Corbus Pharmaceuticals Holding is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Corbus Pharmaceuticals Holding?
The stock symbol for Corbus Pharmaceuticals Holding is "CRBP."
What Is the Corbus Pharmaceuticals Holding Market Cap?
As of today, Corbus Pharmaceuticals Holding market cap is 92.20M.
What Is Corbus Pharmaceuticals Holding's Earnings Per Share (TTM)?
The Corbus Pharmaceuticals Holding EPS (TTM) is -4.23.
From a Technical Analysis Perspective, Is CRBP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.